|NURPF -- USA Stock|| |
USD 2.13 0.00 0.00%
Dr. Joseph Horrigan serves as a Vice President Clinical Development and Medical Affairs of Neuren Pharmaceuticals Limited since August 9, 2012. Dr. Joe Horrigan is a pediatric neuropsychiatrist. Prior to joining Neuren in 2012, Dr. Horrigan served as Assistant Vice President and Head of Medical Research for Autism Speaks, the largest science and advocacy organisation in the US devoted to autism spectrum disorders . In this role he was responsible for developing and implementing a comprehensive strategy in the area of translational medical research in ASD, focusing primarily on Phase IIV clinical trials. Prior to joining Autism Speaks, Dr. Horrigan worked for almost 10 years at GlaxoSmithKline, where he was a Senior Director in the Neurosciences Medicines Development Center. In that capacity, he played a lead role in the development and execution of Phase IIIV clinical development programs across several therapeutic areas in neurology and psychiatry. He also cofounded and led the companywide Medicines for Children Advisory Network at GlaxoSmithKline. Dr. Horrigan is also a Clinical Associate Professor in the Department of Psychiatry at the University of North Carolina at Chapel Hill.
VP Since 2012
61 3 9092 0480 http://www.neurenpharma.com
The company has return on total asset (ROA)
of (31.43) %
which means that it has lost $31.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of 32.01 %
meaning that it generated $32.01 on every $100 dollars invested by stockholders.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Auckland, New Zealand. Neuren Pharmaceuticals is traded on OTC Market in USA.Neuren Pharmaceuticals Limited (NURPF) is traded on OTC Market in USA. It is located in PWC Tower and employs 10 people.
Neuren Pharmaceuticals Leadership Team
|Joseph Horrigan, VP of Clinical Devel. and Medical Affairs|
|Larry Glass, CEO, Managing Director|
|Bruce Hancox, Independent Non-Executive Director|
|Jenny Harry, Non-Executive Independent Director|
|James Shaw, COO|
|Patrick Davies, Non-Executive Independent Director|
|Dianne Angus, Non-Executive Independent Director|
|Richard Treagus, Executive Chairman of the Board|
|Trevor Scott, Independent Non-Executive Director|
|Jon Pilcher, CFO, Company Secretary|
Stock Performance Indicators
Most of Macroaxis users are now bullish on Neuren Pharmaceuticals Limited. What is your trading attitude regarding investing in Neuren Pharmaceuticals Limited? Are you bullish or bearish?
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations